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DARPins as therapeutic tools for Alzheimer’s disease 
Capsule 
Background: The amyloid-beta peptide (Aβ) is 
crucially involved in the onset and progression 
of Alzheimer’s disease (AD). 
Results: A designed ankyrin repeat protein 
(DARPin) was selected to bind and neutralize 
Aβ. 
Conclusion: DARPins can prevent amyloid 
formation and associated neurotoxic effects of 
Aβ. 
Significance: DARPins provide a therapeutic 
potential in the treatment of AD. 
 
Abstract  
Passive immunization with anti-Aβ antibodies 
is effective in animal models of Alzheimer’s 
disease (AD). With the advent of efficient in 
vitro selection technologies, the novel class of 
designed ankyrin repeat proteins (DARPins) 
presents an attractive alternative to the 
immunoglobulin scaffold. DARPins are small 
and highly stable proteins with a compact 
modular architecture ideal for high-affinity 
protein-protein interactions. In this report we 
describe the selection, binding profile and 
epitope analysis of Aβ-specific DARPins. We 
further showed their ability to delay Aβ 
aggregation and prevent Aβ-mediated 
neurotoxicity in vitro. To demonstrate their 
therapeutic potential in vivo, mono- and 
trivalent Aβ-specific DARPins (D23 and 
3xD23) were infused intracerebroventricularly 
into brains of 11 months old Tg2576 mice over 
four weeks. Both D23 and 3xD23 treatments 
were shown to result in improved cognitive 
performance and reduced soluble Aβ levels. 
These findings demonstrate the therapeutic 
potential of Aβ-specific DARPins for the 
treatment of AD. 
 
 
Introduction 
 The amyloid-β peptide (Aβ) is 
considered a central component in the onset 
and progression of Alzheimer’s disease 
(AD)(1). Three major pathways have been 
identified as potential therapeutic channels to 
alleviate the clinical progression and cognitive 
loss: (i) the inhibition of Aβ production from 
amyloid precursor protein (APP), (ii) 
interference with the formation of toxic 
aggregation intermediates and (iii) the 
accelerated elimination of Aβ from the brain 
into the periphery(2, 3). 
From a clinical point of view, these 
concepts strongly support the use of therapeutic 
strategies with proteins that can specifically 
bind, neutralize, and prevent the aggregation 
and propagation of misfolded proteins 
throughout the brain. 
Based on the effective clearance of -
amyloid from the brains of mouse models of 
brain amyloidosis upon repeated A 
immunization(4, 5), numerous immunotherapy 
clinical trials in humans have subsequently 
been initiated(6–8). To-date, more than one 
dozen anti-amyloid immunotherapy clinical 
trials, testing both passive immunotherapy and 
active vaccination strategies, are currently 
underway for the treatment of AD(9).  
Designed ankyrin repeat proteins 
(DARPins) can be effectively selected in vitro 
for binding to a broad variety of target proteins 
with high specificity and affinity, and they have 
been shown to provide new therapeutic 
avenues(10). DARPins are built from several 
ankyrin repeat modules that are tightly packed 
and capped by terminating repeats that shield 
the hydrophobic core, resulting in high stability 
and solubility with a low aggregation 
tendency(11, 12). Additionally, the absence of 
redox-sensitive disulfide bonds has enabled 
DARPins to be used for both intracellular and 
extracellular applications(13, 14) and, 
combined with the lack of endogenous 
receptors, allows an improved fine-tuning of 
tissue distribution and clearance(15) as 
compared to conventional immunoglobulin-
based (IgG) scaffolds. At one-tenth the 
molecular weight of IgGs, DARPins might 
cross the blood brain barrier (BBB) more 
efficiently than antibodies upon peripheral 
administration(16, 17). Unlike IgG-Aβ 
complexes(18), DARPins bound to Aβ will 
probably be removed quickly and efficiently 
from the body, making them ideal amyloid-
lowering therapeutics with a low risk for 
immunogenicity and production of neutralizing 
antibodies following repeated 
administration(19). 
Here we describe the selection of a novel 
class of potential Aβ-specific therapeutics 
based on the ankyrin fold, their affinity 
determination as well as their ability to prevent 
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Aβ aggregation, reduce Aβ-mediated 
neurotoxicity in a cell-culture model and show 
its therapeutic potential in APP transgenic mice 
(Tg2576) in vivo, an animal model of 
Alzheimer’s disease. 
 
Experimental procedures 
Preparation of the amyloid-β peptides. 
Recombinant Aβ1–42 peptide was purchased as 
hexafluoro-isopropanol (HFIP) film from 
rPeptide (Bogart, USA). All biotinylated 
variants (Aβ1–28, Aβ1–40 and Aβ1–42) were 
obtained from Anaspec (Fremont, USA) and 
processed as previously described(20). 
 
Ribosome display selection of DARPins. The 
enrichment of anti-Aβ DARPins was performed 
using previously described N2C and N3C 
DARPin libraries(12). Ribosome display 
selections using decreasing concentrations of 
biotinylated Aβ1–28 (400 nM to 100 nM) as 
target peptide were performed in analogy to 
previous reports(21). The library was subjected 
to a total of four selection cycles, the first of 
which was performed on biotinylated peptide 
bound to a neutravidin-coated microtiter plate 
and the three subsequent rounds were carried 
out in solution using streptavidin-coated 
magnetic particles for pull-down of the ternary 
DARPin-ribosome-mRNA complexes. 
 
Screening and titration ELISA. DARPin 
expression and cell lysis were performed as 
described previously(22). For the analysis of 
individual DARPin clones microtiter plates 
(Corning, Amsterdam, The Netherlands) were 
coated with 66 nM neutravidin followed by 
immobilization of 250 nM of the target 
peptides for 1 h at 4ºC. Bound DARPins were 
detected via an anti-RGS-His6 antibody 
(Qiagen, dilution 1:1000) followed by an anti-
mouse-HRP conjugate (GE Healthcare, dilution 
1:2000). The assay was quantified 
colorimetrically (tetramethylbenzidine in 30 
mM citric acid (1:20)) and stopped with 1 M 
H2SO4. The absorbance at 450 nm was 
recorded against a reference wavelength of 690 
nm with a standard ELISA reader Sunrise™ 
(Tecan, Männedorf, Switzerland). The data 
were fitted to a sigmoid dose-response equation 
using Graph Pad Prism 5 (GraphPad Software, 
USA) to calculate the concentration of half-
maximal binding (EC50). 
 
Competition ELISA. Competition studies 
were performed using a constant concentration 
of 10 nM DARPin with increasing quantities of 
soluble Aβ1–42 (0 to 5000 nM in TBS150 for 1 
h at 4ºC). Target peptide was immobilized at 
250 nM. Signal detection was performed as 
described for titration ELISA. 
 
Epitope mapping by monoclonal antibodies.  
Aβ1–42 at 200 nM was immobilized onto a 
DARPin D23-coated microtiter plate and 
probed with 1 ng µL
–1
 of the monoclonal 
antibodies 6E10, 4G8 (Covance, Basel, 
Switzerland) and 22C4 (in-house). Bound 
antibodies were detected as described for 
titration ELISA. 
 
Epitope mapping by peptide competition. 
Aβ1-28-biotin (250 nM solution) was surface-
immobilized on a neutravidin layer of a 
microtiter plate. DARPin D23 at 50 nM was 
pre-incubated with a 50-fold molar excess of 
the peptide fragments Aβ(-4-6), Aβ (–3–7), 
Aβ(–2–8), Aβ(–1–9), Aβ(1–8), Aβ(2–11), 
Aβ(3–12), Aβ(4–13), Aβ(5–14), Aβ(6–15) 
(peptides&elephants, Potsdam, Germany), 
Aβ(1–11), Aβ(1–16), Aβ(12–28), Aβ(29–40), 
Aβ(31–35), Aβ(33–42), Aβ(1–28), Aβ(1–38) 
(Bachem, Bubendorf, Switzerland) and 
scrambled Aβ1–42 (from N- to C-terminus: 
AIAEGDSHVLKEGAYMEIFDVQGHVFGG
KIFRVVDLGSHNVA) (rPeptide, Bogart, 
USA). The fraction of surface-bound D23 was 
detected as described for titration ELISA. 
 
Aβ aggregation assays. The inhibitory effect 
of equimolar concentrations of D23 on Aβ1-42 
aggregation (both at 5 µM) was assessed in real 
time by thioflavine T (ThT) fluorescence as 
described previously(20). The concentration of 
the Aβ stock solutions were determined 
spectrophotometrically (ε = 1730 M–1 cm–1) 
and, for reasons of reproducibility, used within 
24 hours of preparation(23). The elongation 
rates were mathematically deduced via linear 
regression from the aggregation curves using 
signals from 20 to 80% of the steady state for 
all three experimental conditions. 
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Neurotoxicity assays. The neuroprotective 
effect of D23 on Aβ-mediated neurotoxicity 
(both at 5 µM) was investigated in a cell 
culture model of primary cortical neurons from 
rat embryos (day E18) and performed 
identically to previously published 
protocols(20). Three wells per treatment were 
measured and the assay repeated two more 
times. Data are given as means ± SEM.  
 
Cloning strategy for multivalent DARPins. 
The coding sequence of D23 was excised from 
the expression plasmid pQE30 (Qiagen, 
Hildesheim, Germany) using the restriction 
enzymes BamHI and HindIII (New England 
Biolabs, Ipswich, USA) and subsequently 
inserted into the recipient plasmid (pQI-bi-1_1) 
via a BamHI/HindIII (cassette 1) and BglII and 
BsaI (cassette 2) restriction digestion. Trivalent 
D23 was constructed from bivalent D23 via 
PCR using the primers MVD3_forw (5’-
AAAGAGGAGAAATTAACTATGAGAGGA
TC-3’) and QiBi_MVD_rev (5’-
AAGGATAGGTCTCAAGCTAGAGAGTCA
TTACCCCAGGCGTTTAAGG-3’), the 
resulting amplificate being digested with 
BamHI / BsaI and inserted into the pQI-bi-1_1 
recipient vector via its restriction sites for BglII 
and BsaI. The vector had previously been 
modified to already contain a DARPin in the 5'-
expression cassette. DARPins were genetically 
engineered as head-to-tail fusions and 
expressed in a single open reading frame (ORF) 
as previously described(15). 
 
Surface plasmon resonance. SPR was 
recorded with a Biacore T100 instrument (GE 
Healthcare) similarly to previous descriptions 
using a streptavidin-coated sensor chip and 
Aβ1-42-biotin as immobilized target(12). 
Association and dissociation events were 
measured at a constant flow rate of 30 µL min
–1
 
with analyte concentrations doubling from 0.5 
nM to 512 nM. Kinetic data were globally 
fitted to a 1:1 binding model (D23) or a 
bivalent binding model (3xD23) as part of the 
BIAevaluation software 2.0.3 (GE Healthcare), 
but the complicated kinetics of 3xD23 preclude 
a numeric evaluation.  
 
Animals. This study used Tg2576 transgenic 
mice expressing human APP carrying the 
Swedish mutation K670N/M671L(24). A 12 
hour light–dark cycle was maintained in the 
housing room and, except for the time of 
testing, water and food was provided ad 
libitum.   
 
Cognitive-behavioral testing. At the time of 
testing, mice were weighed and examined for 
general health indicators to ensure that the mice 
were physically able to conduct the cognitive-
behavioral test and to rule out any adverse side 
effects due to the surgical procedure or 
DARPin therapy (cf. Supplementary Material). 
Spatial working memory was assessed in mice 
using the Y-maze (Y-shaped plastic maze, with 
40 cm x 20 cm x 10 cm arm sizes). During a 5 
min trial the sequence of arm entries was 
recorded using the ANY-maze Video Tracking 
System (Stoelting Co., USA). The percent 
alternation was calculated as the ratio of actual 
to possible alternations (defined as the total 
number of arm entries –2) x 100%.  
 
DARPin intracerebroventricular (icv) 
administration via surgical implantation of 
Alzet® osmotic minipumps. Twelve-month-
old Tg2576 mice were deeply anaesthetized, a 
small midline incision was made to expose the 
skull, and a subcutaneous pocket was prepared 
in the midscapular area of the back of the mice 
so that a sterile Alzet
®
 minipump (model 2004) 
filled with DARPin solution or vehicle could be 
inserted. Subsequently, an Alzet Brain infusion 
kit 3 cannula was lowered into the left lateral 
ventricle (coordinates according to bregma; 
AP,–0.2 mm; ML, 0.9 mm; and DV, 2.5 mm) 
and two small screws were placed within the 
skull and dental cement applied to firmly attach 
to the skull. Groups of 19–23 mice received 
icv-infusion over 28 days (equimolar 
concentration of 50 μM) of either D23, 3xD23, 
E2_5 or PBS control. 
 
Biochemical and histochemical analyses. 
Brains from treated mice were obtained as 
described previously(25). The right hemibrain 
was homogenized using a sequential extraction 
protocol using a glass-Teflon homogenizer (20 
strokes, 315 rpm) in RIPA buffer containing 
complete protease inhibitor tablets (Sigma-
Aldrich, Switzerland). The brain extract was 
ultra-centrifuged (100,000 x g at 4ºC for 1 
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hour), supernatant extracted and stored at –
80°C for later biochemical analysis. The 
remaining pellet was frozen on dry ice, 
resuspended in 70% formic acid, sonicated for 
30 s at 30% power and ultra-centrifuged (30 
min). The supernatant was extracted, 
lyophilized, reconstituted in RIPA buffer and 
stored at –80°C for later analysis.  
 
Beta-amyloid analysis. Aβ fragments were 
measured in plasma and brain homogenates 
using a MSD 3plex multi-SPOT Abeta human 
kit (MesoScale Discovery, USA), based on 
electrochemiluminescence detection, with 
capture antibodies specific for Aβx-38, Aβx-40 
and Aβx-42, in accordance to the 
manufacturer’s instructions. The MSD 
SECTOR Imager 6000 reader was used for 
analysis and the MSD DISCOVERY 
WORKBENCH software (Version 3.0.17) with 
the Data Analysis Toolbox was used to 
calculate sample concentrations by comparing 
them against a standard curve (five-parameter 
logistic curve).  
 
Histochemistry. Thioflavin S staining was 
done according to a previously published 
protocol(25). All chemicals were obtained from 
Sigma (St. Louis, MO). Antibody 4G8 
(Covance, Basel, Switzerland) was used at 1 ng 
µL
-1
 to detect amyloid deposits. 
The effect of Aβ addition on neuronal 
morphology was observed in a cell culture 
model of primary cortical neurons from rat 
embryos (day E18) and performed as 
previously described (20). Shortly, cells were 
washed in PBS, fixated by 4% 
paraformaldehyde (in PBS) for 15 min and 
subsequently washed by TBS + 0.05% Triton 
X-100. Cells were blocked with a mixture of 
5% goat- and 5% horse serum (in TBS + 0.05% 
Triton X-100) for 1h at 4°C. Aβ deposits were 
visualized by a polyclonal anti-Aβ antibody 
(Zymed Lab., USA) at 1:500, neurons were 
stained by an anti-MAP2 antibody (Sigma, St. 
Gallen, Switzerland) at 1:1000, followed by 
secondary Cy2-/Cy3-antibodies. 
 
 
Statistical analysis. Data analysis was 
performed using GraphPad Prism 4.03 
software. Tests for normal distribution were 
performed before statistical testing, according 
to the results of the Shapiro-Wilk and the 
Kolmogorov-Smirnov Test for normality. 
Either Student’s t Test or Mann-Whitney U 
Test for 2 sample groups or ANOVA for 
multiple comparisons was performed (followed 
by post-hoc Tukey’s or Mann-Whitney U test). 
A p-value < 0.05 was considered statistically 
significant. Error bars are SEM if not indicated 
differently.  
 
Approval Animal Studies. All animal 
experiments were approved by the veterinary 
office of the Cantonal Health Department 
Zurich. 
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Results 
DARPin D23 specifically binds to soluble 
monomeric Aβ.  
Ribosome display was used to enrich specific 
DARPins against the Aβ peptide. Libraries in 
the N2C and N3C format (with 2 or 3 
randomized repeats between the N- and C-
capping repeats) were subjected to surface-
immobilized C-terminally biotinylated Aβ1–28. 
This truncated Aβ variant was chosen over 
Aβ1–42 for its reduced propensity to form 
aggregates. In every round, the selection 
pressure was increased through a decrease in 
the amount of target peptide, increased washing 
stringency and a reduced number of PCR 
cycles to re-amplify the selected sub-pool. 
From cycle 2 onwards, selection was performed 
in solution to drive the selection of DARPins 
towards recognizing soluble Aβ species 
(Figure 1a). After four cycles, a screening 
ELISA revealed 30 out of 96 clones as specific 
for Aβ1–28 (31%) with negligible reactivity to 
control proteins. These controls comprised 
neutravidin, bovine serum albumin (BSA) and 
directly (=hydrophobically) coated Aβ1-42. All 
specific binders came from the N2C library. 
DNA sequence analysis of twenty randomly 
selected Aβ binders confirmed differences 
mainly in the variable interaction residues and 
with lower frequency also in the N-terminal 
cap. Due to best performance in a series of 
binding experiments, the DARPin termed D23 
was selected as a lead candidate for further 
characterization. A titration ELISA (Figure 1b) 
demonstrated that the selected clone also 
recognized the pathologically relevant variant 
Aβ1–42 with a similar EC50 (17 nM for Aβ1–
28 and 31 nM for Aβ1–42). The binding of 
DARPin D23 to surface-immobilized Aβ was 
specifically competed using a molar excess of 
soluble Aβ1–42 with a 50% drop in binding 
signal at a competitor concentration of < 50 
nM, indicating a low nanomolar affinity of D23 
for soluble Aβ1–42 (Figure 1c). 
 
D23 binds a conformational Aβ epitope 
involving the free N-terminus.  
D23 bound three C-terminally biotinylated 
variants (Aβ1–28, Aβ1–40 and Aβ1–42) with 
similar affinities, but did not recognize N-
terminally biotinylated Aβ1–42 in ELISA (data 
not shown). We utilized the three monoclonal 
antibodies 6E10 (recognizing the N-terminus), 
4G8 (central domain) and 22C4 (C-terminus) 
with known epitopes on the Aβ peptide to 
analyze the DARPin-specific epitope by 
competition experiments(26, 27). The addition 
of these antibodies to immobilized DARPin-Aβ 
complexes revealed that the DARPin-Aβ 
interaction strongly interfered with peptide 
recognition by antibody 6E10 and to a lesser 
extent by 4G8, suggesting that the N-terminal 
Aβ stretch was already bound by DARPin D23 
(Figure 2a). The use of truncated Aβ1-28 
during ribosome display selections focused 
selection on the N-terminal region. Thus, 
DARPin D23 does not interfere with the C-
terminal antibody 22C4.  
 To dissect the DARPin-Aβ interaction 
more closely, a peptide scanning approach with 
soluble short Aβ fragments was used to 
compete the DARPin-Aβ1–28 interaction 
(Figure 2b). A 50-fold molar excess of 
partially overlapping peptide fragments was 
used for competition and only signals below 
those of scrambled Aβ1-42 were regarded as 
specific inhibition. Not only was the 
importance of the N-terminal aspartate residue 
confirmed for high-affinity binding, but we also 
observed that longer peptide fragments (Aβ1–
16, Aβ1–38) with a free N-terminus inhibited 
the interaction more effectively than shorter 
ones, suggesting that the N-terminal stretch is 
part of a conformational, rather than a linear 
epitope. In an immunohistochemical analysis of 
brain sections from APP transgenic mice, we 
observed the specific staining of parenchymal 
and vascular amyloid deposits through D23 but 
not by the unselected control DARPin E2_5 
(Figure 2c). Importantly, D23 does not cross-
react with other brain structures in wild-type 
(WT) mice. 
 
D23 prevents Aβ1–42 aggregation and –
mediated neurotoxicity.  
To study the DARPin’s functional effect on Aβ 
aggregation, equimolar concentrations of Aβ1–
42 were incubated under constant agitation 
either alone or with DARPins D23 and the 
control DARPin E2_5, and thioflavin T (ThT) 
fluorescence signals were recorded over time 
(Figure 3a). While a 5 µM preparation of 
monomeric Aβ1–42 readily aggregated into 
fibrils, the addition of equimolar amounts of 
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D23 – but not E2_5 – was able to significantly 
prolong the lag time and reduce the elongation 
rate of Aβ oligomers thereby delaying the 
formation of higher molecular weight 
aggregation products. The addition of D23 to 
the aggregation assay resulted in a 7-fold 
prolonged elongation rate (elongation rates 
8.58 ± 0.13 min
-1
 (Aβ only), 6.28 ± 0.09 min-1 
(Aβ+E2_5) and 1.17 ± 0.01 min-1 (Aβ+D23), 
whereas E2_5 only had a minor effect on the 
formation of Aβ fibrils. We hypothesize that 
D23 stabilizes the monomeric form of Aβ 
peptide and sequesters it from the dynamic 
aggregation equilibrium. This idea is 
underscored by the observation that D23 does 
not interfere with the Aβ aggregation process if 
added during the log-phase or after the plateau 
has been reached, but delays the aggregation 
process if added in substoichiometric amounts 
at the beginning of the assay (Figure 3b).  
 Aβ-mediated neurotoxicity, as 
measured by the release of cytoplasmic 
proteases from rat primary cortical neurons, 
was quantified either alone or in equimolar 
combination of Aβ with DARPin D23 or the 
control DARPin E2_5. The anti-Aβ DARPin 
could reduce toxicity by about 40%, while 
E2_5 did not show any effect on neurotoxicity 
(Figure 3d). We previously determined a 48 h 
incubation of 5 µM Aβ as most toxic to a 
culture of primary neurons, while an equimolar 
preparation of scrambled Aβ1–42 did not 
induce any toxicity. In microscopy 
experiments, we observed that the addition of 
D23 had a pronounced effect not only on the 
size of the Aβ aggregates, but also prevented 
dendrite retraction thereby contributing to a 
preserved neuronal morphology (Figure 3c). 
 
Multivalent DARPins show higher avidity on 
immobilized Aβ1–42. 
To further optimize Aβ binding, we constructed 
multivalent DARPins that were connected by 
flexible amino acid linkers. All constructs 
eluted as stable monomers from a size 
exclusion column with apparent molecular 
weights of 12 kDa (D23), 30 kDa (2xD23) and 
44 kDa (3xD23) (Figure 4a). In ELISAs with 
coated Aβ1–28, the concentration of half-
maximal signal (EC50 values) of the multivalent 
DARPins was only slightly improved over the 
monomeric DARPin, consistent with only a 
partial multivalent engagement, presumably 
because head-to-tail fusions interfere with the 
unidirectionate display of surface-immobilized 
Aβ1–28  (data not shown).  
 An analysis of the association and 
dissociation phases via surface plasmon 
resonance (SPR) revealed substantial 
differences in the association and dissociation 
phases of the individual constructs (Figure 4b 
and d). While the monovalent DARPin D23 
(Figure 4b) showed very fast equilibration 
precluding a kinetic evaluation, the trivalent 
construct gave rise to slower and multiphasic 
dissociation kinetics, indicating multivalent 
binding to the immobilized Aβ1–42 on the 
sensor chip. The monovalent construct was 
evaluated by measuring the plateau levels, 
indicating a KD of 1.589 x 10
-7
 M (Figure 4c). 
Since the observed association phase is the sum 
of the association and the dissociation process, 
they appear slower for the trivalent construct, 
simply because koff gets slower. Due to the 
various modes of multivalent binding, the 
sensorgrams of 3xD23 cannot be satisfactorily 
fit and thus no kinetic constants are reported 
(Figure 4d).  
 Encouraged by the long-term stability 
and preservation of Aβ binding activity of D23 
under physiological conditions of at least three 
weeks (data not shown), in accordance with 
previous descriptions(15), we tested the effect 
of intracerebroventricular infusions of mono- 
and trivalent DARPin constructs in Tg2576 
mice, which express the human APP695 
isoform with the double mutation 
K670N/M671L(24). 
 
Intracerebroventricular DARPin infusion 
improves cognition and lowers the soluble 
Aβ pool in a mouse model of brain 
amyloidosis. 
Two weeks after intracerebroventricular 
implantation of osmotic pumps, all Tg2576 
mice underwent Y-maze behavioral-testing, a 
paradigm for testing working memory in APP 
transgenic mice(28, 29). Cognitive assessment 
in the Y-maze revealed a significant 
improvement in percentage alternation, as a 
measure for memory function upon treatment 
with both mono- and trivalent anti-Aβ 
DARPins, as compared to E2_5 and PBS 
treated control mice (p<0.05, Figure 5a). The 
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number of total arm entries and distance 
travelled did not differ between groups (data 
not shown), excluding a confounding effect due 
to altered activity of the mice. No differences in 
general health measures or any treatment-
induced side effects were observed across all 
experimental groups. 
 After four weeks of infusion, animals 
were perfused and compact plaque load in the 
cortex was quantified by Thioflavin S 
histochemical analysis of brain sections. 
Already after four weeks of treatment a 
reduction of plaque area by 23% in both D23 
and 3xD23 mice was revealed, as compared to 
E2_5 and PBS-treated mice, but did not reach 
statistical significance (Figure 5b). As a next 
step, we determined Aβ levels biochemically in 
two sequentially extracted protein fractions 
from hemi brain tissue (Figure 5c-h). In 
agreement with our histological findings, D23 
and 3xD23-treated mice showed a significant 
reduction of Aβ1–40 (by 21% and 16%), of 
Aβ1–38 (by 21% and 16%) and of Aβ1–42 (by 
31% and 25%), respectively, in the detergent-
soluble (RIPA-soluble, Figure 5c-e) protein 
fraction, as compared to E2_5 and PBS control 
mice. A similar trend was observed in the 
detergent-insoluble (formic acid soluble, 
Figure 5f-h) Aβ pool, though the effect was 
not significant due to the initiation phase of 
amyloid deposition and concomitantly higher 
variability of plaque load in these animals. 
These findings provide the first in vivo 
evidence that DARPins may successfully 
reverse Aβ-mediated cognitive deficits in a 
transgenic mouse model of brain amyloidosis 
and that the continuous infusion of DARPins 
can have a modulatory effect on brain Aβ 
levels. 
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Discussion 
Ribosome display of combinatorial DARPin 
libraries has been utilized to select for DARPin 
binders against a diverse set of folded target 
proteins(10), but selection against peptide 
antigens without defined structure has not been 
reported. In this study we were able to select a 
DARPin binder, termed D23, which showed 
nanomolar affinities for the Aβ peptide in both 
direct and competition ELISA assays. 
Therefore, D23 was selected as the lead 
candidate for further characterization and to 
test the therapeutic potential of DARPins 
administered in vivo for the treatment of brain 
amyloidosis in APP transgenic mice.  
 The binding of D23 to surface-
immobilized Aβ1–28 and Aβ1–42 was shown 
to be in the low nanomolar range; however the 
physiologically more relevant specific binding 
to Aβ in solution (as it principally occurs in 
prodromal phases of AD in vivo) is difficult to 
address and needed to be clarified. Aβ can 
occur in solution in various quaternary 
structures, ranging from soluble monomers(30), 
oligomeric intermediates(31) to fibrillar 
states(32). Since these forms differ in 
conformation, accessibility of epitopes and the 
possibility of bi- or even multivalent 
interactions, it is not surprising that Aβ-binding 
macromolecules can display varying 
specificities for Aβ, depending on its state. 
 A competition assay using freshly 
dissolved monomeric Aβ1–42 as competitor 
confirmed the observations made with surface-
immobilized Aβ and suggested a KI value of 
approximately 50 nM. This inhibition was 
specific and not due to general hydrophobic 
interactions, as the use of scrambled Aβ1–42 
did not significantly reduce D23 binding to the 
surface-immobilized target (Figure 2b). We 
had noticed that C-terminal amino acid 
extensions (to result in a peptide longer than 
the 28 residues used for selection) resulted in 
slightly decreased apparent affinities, possibly, 
because some molecules had formed aggregates 
and were not able to bind. 
 We demonstrated that the free N-
terminus of the peptide must be involved in 
D23 binding. Furthermore, we could confirm 
the N-terminal Aβ domain to be involved in 
DARPin recognition, as of several monoclonal 
antibodies with comparable affinities 
tested(33), 6E10 was most impaired in binding 
the complex of D23 and Aβ1–42 and thus 
competes for the epitope. A peptide scanning 
approach enlarged this binding region to the 
central Aβ domain, suggesting the binding of a 
discontinuous rather than linear epitope, as 
generally described for DARPins binding to 
different targets(10, 12, 34). Aβ is thought to 
contain a largely unstructured N-terminus 
(residues 1–11) and two domains spanning 
residues 12–21 and 24–42, respectively, with 
varying contacts among each other, whereas the 
connecting residues (22 and 23) face the 
solvent(35). The particular binding mode of 
D23 is thus different from that of previously 
reported monoclonal antibodies that recognize 
a linear stretch of the Aβ peptide and also 
cross-react to APP(36) (at least 6E10 and 4G8).  
 The targeting of conformational Aβ 
epitopes is highly advantageous for the 
specificity of anti-Aβ therapeutics. As the 
conformation of the free monomeric Aβ 
peptide is most likely different from the one 
inside APP, D23 cross-reactivity to APP is 
limited (as indeed observed in cell-culture 
binding experiments, data not shown) and 
could enable repeated dosing without the risk 
of peripheral or central APP to either act as off-
target scavenger or to create an immune 
reaction against APP-carrying cells. To 
determine the binding characteristics of D23 ex 
vivo, we performed immunohistochemical 
analyses with GFP-fused DARPins on brain 
tissue from an ArcAβ mouse model of AD 
(Figure 2c). The staining of Aβ deposits in this 
model with an increased proportion of vascular 
amyloid demonstrated D23 to preferentially 
bind the cross-β pleated dense central cores of 
the amyloid deposits, in contrast to more 
diffuse anti-Aβ antibody stainings. Such 
findings underscore D23’s recognition of 
discontinuous amino acid stretches on both the 
N-terminal and central domain of the Aβ 
peptide that still exist in both the monomeric 
and aggregated form. Non-specific adherence 
of the DARPin scaffold to the ‘sticky’ amyloid 
plaques could be excluded, as no tissue 
reactivity was observed with the non-specific 
E2_5 control DARPin.  
 As a first test of the DARPin's in vitro 
activity, we were able to demonstrate that D23 
delays Aβ aggregation (Figure 3a), using ThT 
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aggregation assays. In contrast, the addition of 
D23 during the lag phase or after complete 
fibrillization did not lead to any decrease in 
ThT signal. This likely indicates that D23 binds 
to and stabilizes a monomeric form of Aβ and 
excludes it from the aggregation process. We 
were further able to demonstrate that D23, but 
not the control DARPin E2_5, when 
administered into the medium of rat primary 
cortical neuron cultures, could reduce Aβ-
mediated neurotoxicity and preserve neuronal 
morphology (Figure 3b,c). 
 To optimize D23 binding behavior for 
potential therapeutic use, a trivalent DARPin 
was engineered by fusing three monovalent 
units of D23 into one continuous open reading 
frame. While these constructs showed similar 
stability and resistance against degradation and 
bound the Aβ peptide with nanomolar affinity, 
surface plasmon resonance kinetic analysis 
revealed differences in on- and off-rates for 
each individual construct (Figure 4b-d). The 
increased molecular weight of multivalent 
DARPins reduces diffusion and potentially 
limits their tissue penetration, whereas their 
multivalency prolongs the half-life of DARPin-
Aβ complexes in case of polymeric Aβ surfaces 
such as oligomers and fibrils. 
 Finally, we were able to demonstrate 
the in vivo therapeutic potential of D23 and 
3xD23 in Tg2576 mice. Following the 
intracerebroventricular infusion of mono- and 
trivalent DARPin constructs over a 28-day-
treatment, D23- and 3xD23-treated mice 
showed improved cognitive performance, 
compared to mice treated with the control 
DARPin E2_5 or PBS. These results were 
supported by histochemical analyses, showing 
a trend for reduction of plaque deposition in 
both D23- and 3xD23-treated mice (Figure 
5b). However, as we infused anti-Aβ DARPins 
in Tg2576 mice already at 11 months of age, 
the majority of the amyloid burden is still 
present in soluble Aβ forms, explaining the 
limited number of amyloid deposits found in 
the cortices of treated animals.  
 This preventive treatment paradigm 
was accompanied by a biochemical analysis 
that showed significant reductions of brain Aβ 
levels for both D23- and 3xD23-treated mice 
with the most pronounced modulatory effects 
on the soluble Aβ pool (Figure 5c-e). 
Interestingly, despite anti-Aβ multivalency, 
3xD23 did not perform better than its 
monovalent counterpart D23 in vivo. There are 
several possible explanations for this finding. If 
the action of D23 predominantly involves 
binding of monomeric Aβ, then a trimer would 
have, at most, the same activity as three 
monomers, but avidity would play no role. It is 
also possible that the increased molecular 
weight of 3xD23 could have restricted its rapid 
tissue penetration such that it could not 
sufficiently benefit from the additional 
interaction surfaces(15, 37).  
 DARPins lack the Fc domain intrinsic 
to the immunoglobulin G molecule, which has 
been shown to activate resident microglia in the 
vicinity of antibody-decorated amyloid 
deposits(29, 38, 39). Activated microglia can 
degrade fibrillar Aβ by lysosomal proteolysis, 
but local inflammatory reactions might, at 
worst, result in microhemorrhages (29, 40, 41). 
The biological activity of DARPins could be 
based on their association with these deposits, 
and they could sterically block recruitment of 
Aβ monomers to the amyloid plaque by binding 
to monomers or they could clear amyloid 
deposits independent of microglia in analogy to 
other molecular scaffolds without functional Fc 
domain(42–44). DARPin-mediated Aβ removal 
would have to rely on the capture and 
elimination of these species from the central 
nervous system via the bulk flow of interstitial 
fluid(45).  
 Our findings demonstrate the 
therapeutic potential of Aβ-specific DARPins 
for the treatment of Alzheimer’s disease. With 
the advent of recombinant protein expression 
and efficient in vitro selection technologies, 
this novel class of engineered protein scaffolds 
presents attractive opportunities for both 
diagnostic and therapeutic use. If longer serum 
half-lives are required, this could be achieved 
by site-specific PEGylation(15) or by hijacking 
an abundant serum protein with long half-life, 
like albumin or immunoglobulin G through 
peptide tags that bind to them to escape 
glomerular filtration(46, 47). Knowing the 
recent set-backs of human anti-Aβ therapies, 
this study opens new avenues away from 
antibodies towards DARPins to fight brain 
amyloidosis effectively. 
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Figure legends 
 
Figure 1 Selection of anti-Aβ DARPins through ribosome display in vitro. (a) DARPin libraries were 
selected against decreasing amounts of the biotinylated Aβ1-28 peptide via ribosome display in four 
selection rounds. Biotinylated peptides were presented via neutravidin immobilized on a microtiter plate 
(round 1) or recovered from solution through streptavidin-coated magnetic particles in all subsequent 
rounds.  DNA was re-amplified at the end of each round with decreasing numbers of PCR cycles (arrow 
numbers). After four rounds, E. coli was transformed, and individual clones were analyzed for Aβ binding 
activity through ELISA. (b) ELISA titration with increasing amounts of DARPin D23 binding to 
immobilized Aβ1-28 and Aβ1-42. The half maximal intensity (EC50) is determined at 17 nM (Aβ1-28) and 
31 nM (Aβ1-42). A non-selected library member, E2_5, did not bind Aβ1-42 at any concentration. (c) 
Inhibition of DARPin D23 binding to immobilized Aβ1-28-biotin by increasing concentrations of the 
soluble non-biotinylated peptide Aβ1-42. The competition showed half-maximal inhibition at 
approximately 50 nM Aβ1-42. Data in b-c are means from three independent experiments; represented as 
means  SD. 
 
Figure 2 Determination of the DARPin D23 epitope and binding to amyloid deposits in ex vivo murine 
brain tissue. (a) In a direct ELISA, Aβ1-42 was bound to immobilized DARPin D23, and the accessibility 
of different parts of the peptide was probed with monoclonal anti-Aβ antibodies directed against the N-
terminus (6E10), central part (4G8) or C-terminus (22c4) of the peptide. The lowest binding signal was 
observed for antibody 6E10, specific for the N-terminus of Aβ. (b) Determination of the Aβ epitope 
recognized by D23 by competition with a 50-fold molar excess of Aβ-derived peptide fragments. 
Biotinylated Aβ1-28 peptide was immobilized via streptavidin and ELISA signals were normalized to a 
non-competed control. Inhibition was considered specific if signals were below the one of scrambled Aβ1-
42 control (dotted line). (c) GFP-fused DARPin D23 specifically recognized amyloid-β plaques in brain 
slices from transgenic ArcAβ mice. The specificity of plaque binding by the selected DARPin D23 was 
confirmed by applying DARPins C-terminally fused to superfolder GFP (sfGFP) onto brain sections from 
wild-type mice (A-C) and ArcAβ (D-F) transgenic mice. The control DARPin E2_5 did not show any 
binding activity (G-H). D23 recognized vascular (arrow) and parenchymal (arrowhead) amyloid deposits 
without cross-reactivity to WT brain structures. First row: DARPin binding (GFP channel); middle row: 
anti-Aβ antibody binding (antibody 4G8, Cy3 channel); bottom row: merge of GFP- and Cy3-channel. 
Data in a-b are means from three independent experiments; represented as means  SD. 
 
Figure 3 Inhibition of Aβ aggregation and Aβ-mediated neurotoxicity through D23 addition. (a) The 
inhibitory effect of DARPin D23 on Aβ1-42 aggregation was monitored by thioflavin T fluorescence 
(ThT). Equimolar concentrations of Aβ1-42 and DARPins D23 or E2_5 (5 µM each) were co-incubated 
and ThT fluorescence monitored for 3 hours at 489 nm. The assays were performed in triplicates in stirred 
cuvettes. Data presented as means ± SD. (b) Half-equimolar concentrations of D23 were added at different 
timepoints during the exponential growth phase of the Aβ fibrils. The addition occurred at t1=20 min (red 
curve) and t2=37 min (gray curve). (c) Effects of Aβ1-42 and DARPin addition on neuronal morphology. 
Upper panels: neurons were incubated either in the absence (-) or in the presence (+) of 5 µM Aβ1-42. Aβ 
deposits were stained orange (polyclonal anti-Aβ antibody), neurons green (antibody to MAP2). Lower 
panels: co-incubation of Aβ1-42 with Aβ-specific DARPin D23 (left, lower panel) or control DARPin 
E2_5 (right, lower panel). Inlays to all four micrographs show magnifications of anti-MAP2 stained 
neurons from the aforementioned treatment conditions. Scale bars correspond to 20 µm. (d) Primary rat 
neurons (day 5 in vitro) were co-incubated with equimolar amounts of recombinant Aβ1-42 and DARPins 
D23 or E2_5 (all components 5 µM). After 48 hours the level of Aβ1-42-mediated toxicity was assessed 
by the activity of neuronal proteases (cleaving luciferin off a coupled substrate). D23 is able to 
significantly decrease Aβ1-42-mediated cytotoxicity as compared to controls (mean ± SEM; * p < 0.05; 
One-way ANOVA, followed by Tukey's test).  
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Figure 4 Stability and binding of multivalent DARPin constructs to immobilized Aβ1-42. (a) Multivalent 
DARPin variants of D23 were constructed by fusing monovalent units by (Gly4Ser)2 linkers. These 
constructs were well expressed and eluted as monomeric peaks from size exclusion chromatography with 
apparent molecular weights of 12 kDa (VE=1.86 mL, D23), 30.4 kDa (VE= 1.57 mL, 2xD23) and 44.3 kDa 
(VE=1.45 mL, 3xD23). The elution volumes of MW standards are shown above the graph. (b) Surface 
plasmon resonance (SPR) kinetics of monovalent DARPin D23 on surface-immobilized Aβ1-42. The C-
terminally biotinylated peptide Aβ1-42 was immobilized on a streptavidin sensor chip and monovalent 
DARPin D23 was injected in duplicates at increasing concentrations of 1 to 128 nM. Association and 
dissociation phases were recorded and the sensorgrams were globally fitted (red dotted lines) to a 1:1 
binding model. (c) The equilibrium binding constant (KD) of monovalent D23 was determined as 1.59 x 
10
-7
 M from evaluation of the plateau heights as function of D23 concentration. (d) SPR kinetics of 
trivalent DARPin on surface-immobilized Aβ1-42. Trivalent 3xD23 was attempted to be fitted with a 
bivalent binding model (red dotted lines), but the more complicated situation with several modes of 
bivalent and possibly trivalent binding are not described by the fits well enough and preclude a numerical 
evaluation. 
 
Figure 5 Restoration of memory deficits in APPSwe transgenic mice by DARPin treatment and influence 
on soluble brain Aβ levels. (a) Two weeks after continuous intracerebroventricular infusion of monovalent 
(hatched), trivalent (black) DARPins, non-specific DARPin (E2_5, grey) or PBS (white), Tg2576 mice 
were cognitively assessed in a Y-maze experiment by recording the number of alternating arm entries. (b) 
After four weeks of anti-Aβ therapy, animals were sacrificed and the brain cortical area covered by 
amyloid deposits determined. DARPin treatment appeared to influence amyloid deposition, but did not 
reach significance.  (c)-(h) Total levels of both soluble (RIPA dissolved, c-e) and insoluble (formic acid 
dissolved, f-h) brain Aβ1-38, Aβ1-40 and Aβ1-42 levels were measured with a human Abeta triplex kit. 
Animals per group n = 10-12. Data shown as mean ± SEM. Statistical analysis by ANOVA followed by 
Mann Whitney U test; * p<0.05; # trend p<0.10. 
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Figure 5 
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